86 results about "Amicyanin" patented technology

Conventional food compositions for use in making baked goods and extruded food products are improved by reducing the carbohydrate content. This is done by substituting the conventional flour in whole or in part by a combination of starch that is resistant to amylase digestion and / or from about 1-150 baker's percent of a first proteinaceous ingredient comprising at least about 70% by weight protein, and a second proteinaceous ingredient selected from the group consisting of (i) between about 0.5-100 baker's percent of a wheat protein isolate product; (ii), between about 0.5-100 baker's percent of a wheat protein concentrate product; (iii) between about 0.5-100 baker's percent of a devitalized wheat gluten product; (iv) between about 0.5-20 baker's percent of a fractionated wheat protein product; (v) between about 0.5-20 baker's percent of a deamidated wheat gluten product; (vi) between about 0.5-30 baker's percent of a hydrolyzed wheat protein product; and (vii) any combination of ingredients (i) to (vi).

The present invention relates to methods of treatment of mammalian conditions characterized by decreases in bone mass with conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs containing PTH polypeptide derivatives containing at least one Glu or Lys substitution at position 6 and / or 10, some with installed lactam bridges between the side chains of Lys and Glu. The invention provides derivatives of PTH (1-34), PTH(1-33), PTH(1-32), PTH(1-31), PTH(1-30), PTH(1-29), PTH(1-28), PTH(1-27), PTH(1-26), PTH(1-25), PTH(1-24), PTH(1-23), PTH(1-22), PTH (1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), PTH(1-10) and PTH(1-9) polypeptide. The invention also provides methods of preparing the PTH analogs. Further, the invention encompasses treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.

A method and composition prevents, controls and ameliorates urinary tract infections caused by E. coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyanidin containing concentrate, D-mannose and a proprietary probiotic blend. The cranberry derivative or proanthocyanidin containing concentrate comprises from about one percent (1.0%) by weight to about 95 percent (95.0%) by weight on a dry weight basis. The composition is formulated for delivering a D-mannose unit dosage between about 0.5 to about 5.0 grams per dose. A proprietary probiotic blend is included to provide 5 billion CFU per dose.

The invention discloses a method for obtaining plant hairy roots with high anthocyanin content, and relates to the technical field of plants. The method comprises the following steps of respectively constructing an MYB gene and a bHLH gene AmDEL for regulating anthocyanin anabolism into a carrier PJAM 1502 and a carrier pK7WG2D to obtain PJAM1502::AmROS1 and pK7WG2D::AmDEL; converting PJAM1502::AmROS1 and pK7WG2D::AmDEL into agrobacterium rhizogenes to obtain the agrobacterium rhizogenes containing plasmids PJAM1502::AmROS1 and pK7WG2D::AmDEL; and inducing out hairy roots with high anthocyanin content after utilizing the converted agrobacterium rhizogenes to infect plant tissue organs for co-culturing and screening-culturing. The method disclosed by the invention simultaneously expresses transcription factor MYB gene and bHLH gene for regulating anthocyanin anabolism to obtain the special plant hairy roots with high anthocyanin content.

Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1). The inhibition constant of OM99-2 is 1.6×10−9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, as well as the importance of the various residues in binding. This information can be used by those skilled in the art to design new inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology, to design new inhibitors to memapsin 2, useful in diagnostics and for the treatment and / or prevention of Alzheimer's disease.

Disclosed herein is a composition that is suitable for influencing electromagnetic radiation on cutaneous extracellular matrix protein production. The composition contains (a) a proanthrocyanin, a polyphenol or a proanthrocyanin / polyphenol-containing plant extract, absorbed or adsorbed onto an inert carrier, where component (a) is responsive to UV, IR or visible light; (b) a photo-activatable amino acid or amino acids blend; and (c) a dermatologically-acceptable vehicle, wherein component (a) is present in an amount of from about 15 wt % to about 35 wt % based on the total amount of component (a) and component (b), said component (b) is present in an amount of from about 65 wt % to about 85 wt % based on the total amount of component (a) and component (b), and said component (c) is present in an amount of from about 90 wt % to about 99.95 wt % based on the total weight of the composition.

The present invention relates to a novel method for quantifying procyanidin and flavan-3-ols contained in natural products, foods and drinks, pharmaceuticals and / or cosmetics. The present invention provides a method for quantifying procyanidin (a generic name for a mixture of catechin n-mer; n≧1) contained in test samples such as natural products, foods and drinks, pharmaceuticals and / or cosmetics, which comprises a) pretreating a test sample using a column to remove contaminants which affect the analysis of procyanidin and flavan-3-ol; and b) effecting high performance liquid chromatography (HPLC) to separate and quantify procyanidin and flavan-3-ols in the solution treated to remove contaminants during the above pretreatment step a).

Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

The invention discloses an ornamental collard anthocyanin relevant R2R3-MYB gene BoMYB and an expression vector and application thereof. The cDNA sequence of the BoMYB gene is shown as SEQ ID NO.1. The BoMYB gene can be used for regulating and controlling the biosynthesis of the anthocyanin. The collard anthocyanin purple leaf property regulating and control gene BoMYB is obtained by a homologouscloning method; a real-time fluorescent quantitative PCR method is used for studying the expression mode of the BoMYB gene in different tissues; analysis results show that the tissue specificity is realized in the BoMYB expression; the gene expression quantity is relevant to the anthocyanin content in each tissue. The heterologous expression verification in arabidopsis proves that the accumulationof the anthocyanin in the transgenic arabidopsis plants can be increased through the BoMYB overexpression.